A Technician’s Wary Eye On Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. (ICPT) may indeed have the $5B blockbluster liver drug that RBC Capital Markets claimed in hiking its price target on the stock from $425 to $500. Gilead (GILD) may indeed buy out the company. Other analysts like Leerink Partners who raised its price target from $270 to $445, and Deutsche Bank who … Read more